Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 101371
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.101371
Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
Jian-Lin Lu, Yuan Cheng, Zi-Ling Xu, Gui-Xiang Qian, Ming-Tong Wei, Wei-Dong Jia
Jian-Lin Lu, Zi-Ling Xu, Ming-Tong Wei, Wei-Dong Jia, Department of Hepatic Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, Anhui Province, China
Yuan Cheng, Gui-Xiang Qian, Department of Hepatic Surgery, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Science and Medicine, University of Science and Technology of China, Hefei 230001, Anhui Province, China
Co-first authors: Jian-Lin Lu and Yuan Cheng.
Author contributions: Lu JL, Cheng Y, and Jia WD contributed to conception and design, and wrote and revised the manuscript; Lu JL and Cheng Y analyzed and interpreted the data, and contributed equally as co-first authors; Lu JL, Xu ZL, Qian GX, and Wei MT contributed to data acquisition; and all authors have approved the final version to be published.
Supported by the Key Research and Development Projects of Anhui Province, No. 202104j07020048; and National Key Research and Development Program of China, No. 2022YFA1304500.
Institutional review board statement: This study was approved by the Ethics Committee of the Anhui Provincial Hospital Affiliated to Anhui Medical University (No. 2023-RE-392).
Informed consent statement: The need for informed consent was waived owing to the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and/or analyzed in the current study are not publicly available because of privacy concerns; however, masked information is available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Dong Jia, MD, PhD, Professor, Department of Hepatic Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, China. jwd1968@ustc.edu.cn
Received: September 12, 2024
Revised: January 25, 2025
Accepted: February 13, 2025
Published online: April 15, 2025
Processing time: 194 Days and 9.7 Hours
Core Tip

Core Tip: The postoperative combined therapy with anti-programmed death 1/anti-programmed death ligand 1 and anti-vascular endothelial growth factor receptor agents has not been shown to be effective but not significant in reducing early recurrence in patients with hepatitis B virus-associated hepatocellular carcinoma. And thorough evaluation and close monitoring of liver function and hepatitis B-related markers in patients with hepatitis B virus-associated hepatocellular carcinoma are critical when implementing this combined treatment approach.